Polyphor to Present at the UBS Global Healthcare Virtual Conference
- Global shares near record on U.S. infrastructure bill
- Nike (NKE) Tops Q4 EPS by 43c
- Banks clear Fed stress test; paving way to boost buybacks, dividends
- FedEx (FDX) Tops Q4 EPS by 2c, Offers FY22 Guidance
- Didi IPO Pricing: Seeking to Raise $4 Billion at Valuation of $62 Billion to $67 Billion, Books Already Fully Covered on First Day
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
ALLSCHWIL, Switzerland, May 18, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021. Gokhan Batur, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A replay of the presentation will be available for 30 days following the conclusion of the event.
For further information please contact:
|Hernan LevettChief Financial OfficerPolyphor Ltd.+41 61 567 16 00IR@polyphor.com||Mary-Ann ChangLifeSci AdvisorsTel: +44 7483 284 firstname.lastname@example.org|
Bernhard SchmidLifeSci Advisors+41 44 447 12 email@example.com
Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CrossFirst Announces Details of Second Quarter 2021 Earnings Results, Webcast and Conference Call
- Fury Announces Results of Annual General and Special Meeting of Shareholders
- Fortress Technologies Inc. Provides Corporate Update on Strategic Venture with GAM
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!